Pay in 4 interest-free payments of $6.57 Learn more
Ships within 48 hours · Estimated delivery Oct 3 - Oct 8
The standalone fat-loss evidence is weak
Pantanetti P, Ronconi V, Sguanci M, Palomares SM, Mancin S, Tartaglia FC, et al
Novo Nordisk A/S: Oral semaglutide 50 mg achieved 15.1% weight loss (17.4% if all people adhered to treatment) in adults with obesity or overweight in the OASIS 1 trial
With adults who take GLP-1 drugs consuming approximately 16% 39% less calories than during non-GLP-1 use 4 , its easy to understand why QSR brands may be panicking about potential revenue loss created by the release of these wonder drugs
US$ 22.54
US$ 28.24
US$ 22.13
US$ 29.79
